Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 6/20 | 0.66 |
| ▸ | DRD3 | P35462 | 6/20 | 0.66 |
| ▸ | DRD4 | P21917 | 2/20 | 0.58 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.58 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.58 |
| ▸ | CA1 | P00915 | 4/20 | 0.55 |
| ▸ | CA2 | P00918 | 4/20 | 0.55 |
| ▸ | ACHE | P22303 | 4/20 | 0.55 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.52 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.49 |
| ▸ | HTR1A | P08908 | 1/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4001498 | 1.00 | DRD2 (0.66) | DRD2DRD3DRD4MTNR1AMTNR1B | |
| SCHEMBL6403014 | 1.00 | DRD2 (0.66) | DRD2DRD3DRD4MTNR1AMTNR1B | |
| SCHEMBL7958191 | 0.93 | DRD2 (0.58) | DRD2DRD3DRD4MTNR1AMTNR1B | |
| SCHEMBL8765765 | 0.90 | DRD2 (0.58) | DRD2DRD3DRD4MTNR1AMTNR1B | |
| SCHEMBL4000913 | 0.90 | DRD2 (0.58) | DRD2DRD3DRD4MTNR1AMTNR1B | |
| SCHEMBL4000915 | 0.90 | DRD2 (0.58) | DRD2DRD3DRD4MTNR1AMTNR1B | |
| SCHEMBL23343811 | 0.85 | DRD2 (0.54) | DRD2DRD3DRD4MTNR1AMTNR1B | |
| SCHEMBL3961628 | 0.85 | DRD2 (0.54) | DRD2DRD3DRD4MTNR1AMTNR1B | |
| SCHEMBL8983525 | 0.81 | DRD2 (0.68) | DRD2DRD3DRD4MTNR1AMTNR1B | |
| SCHEMBL10977596 | 0.80 | DRD2 (0.68) | DRD2DRD3DRD4MTNR1AMTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1963292-A2 | ORGANIC COMPOUNDS | Novartis Pharma AG (CH) | 2008-09-03 | — | — | EP | claimed |
| WO-2007067615-A2 | THIADIAZOLE DERIVATIVES AS ANTIDIABETIC AGENTS | NOVARTIS AG (CH) | 2007-06-14 | — | — | WO | claimed |
| EP-2772476-B1 | METHOD FOR PRODUCING OPTICALLY ACTIVE ALCOHOL | HAMARI CHEMICALS LTD (JP) | 2017-01-11 | — | — | EP | disclosed |
| US-9174899-B2 | Method for producing optically active alcohols | HAMARI CHEMICALS, LTD. (JP) | 2015-11-03 | — | — | US | disclosed |
| US-20140296584-A1 | Method for Producing Optically Active Alcohols | HAMARI CHEMICALS, LTD. (JP) | 2014-10-02 | — | — | US | disclosed |
| EP-2772476-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE ALCOHOL | Hamari Chemicals, Ltd. (JP) | 2014-09-03 | — | — | EP | disclosed |
| EP-1553170-B1 | NOVEL CARBONYL REDUCTASE, GENE THEREOF AND METHOD OF USING THE SAME | KANEKA CORP (JP) | 2012-06-27 | — | — | EP | disclosed |
| EP-1963292-B1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2012-02-22 | — | — | EP | disclosed |
| US-7700633-B2 | Organic compounds | NOVARTIS AG (CH) | 2010-04-20 | — | — | US | disclosed |
| US-7531329-B2 | Carbonyl reductase, gene thereof and method of using the same | KANEKA CORPORATION (JP) | 2009-05-12 | — | — | US | disclosed |
| US-20080262050-A1 | Organic Compounds | NOVARTIS AG (CH) | 2008-10-23 | — | — | US | disclosed |
| EP-1963292-A2 | ORGANIC COMPOUNDS | Novartis Pharma AG (CH) | 2008-09-03 | — | — | EP | disclosed |
| US-20070178565-A1 | Novel carbonyl reductase, gene thereof and method of using the same | KANEKA CORPORATION | 2007-08-02 | — | — | US | disclosed |
| WO-2007067615-A2 | THIADIAZOLE DERIVATIVES AS ANTIDIABETIC AGENTS | NOVARTIS AG (CH) | 2007-06-14 | — | — | WO | disclosed |
| US-7220564-B2 | Carbonyl reductase, gene thereof and method of using the same | KANEKA CORPORATION (JP) | 2007-05-22 | — | — | US | disclosed |
| US-20060035357-A1 | Novel carbonyl reductase, gene thereof and method of using the same | KANEKA CORPORATION (JP) | 2006-02-16 | — | — | US | disclosed |
| US-20050153408-A1 | 7-substituted-2-tetralone or bisulfite adduct is reduced microorganism (Candida) to optically active 7-substituted-2-tetralol;sulfonyl group is introduced to hydroxy group to form optically active 7-substituted-2-sulfonyloxytetralin; nitrogen substituent is introduced via ammonia; industrial scale | KANEKA CORPORATION (JP) | 2005-07-14 | — | — | US | disclosed |
| EP-1553170-A1 | NOVEL CARBONYL REDUCTASE, GENE THEREOF AND METHOD OF USING THE SAME | KANEKA CORPORATION (JP) | 2005-07-13 | — | — | EP | disclosed |
| EP-1457570-A1 | PROCESS FOR PREPARATION OF 2-AMINOTETRALIN DERIVATIVES AND INTERMEDIATES THEREOF | KANEKA CORPORATION (JP) | 2004-09-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070178565-A1 | Novel carbonyl reductase, gene thereof and method of using the same | PYCR1, CBR3, CBR1 | DRD2 3670/4885DRD3 3506/4885DRD4 2353/4885 |
| US-20080262050-A1 | Organic Compounds | PTPRS, PTPRO, PTPRC | DRD2 4698/4885DRD3 4750/4885DRD4 4789/4885 |
| US-20140296584-A1 | Method for Producing Optically Active Alcohols | ADH5, ADH1C, ADH1A | DRD2 114/4885DRD3 127/4885DRD4 61/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.